Why does hyperkalemia occur in adults taking finerenone, especially older patients with stage 3–4 chronic kidney disease, type 2 diabetes, or concomitant ACE inhibitor or ARB therapy?

Why Hyperkalemia Occurs with Finerenone

Finerenone causes hyperkalemia by blocking the mineralocorticoid receptor in the distal nephron, which reduces aldosterone-mediated potassium excretion through the principal cells of the collecting duct. 1

Mechanism of Hyperkalemia

Primary Mechanism: Reduced Renal Potassium Excretion

• Finerenone blocks mineralocorticoid receptors in the kidney, preventing aldosterone from stimulating sodium reabsorption and potassium secretion in the distal convoluted tubule and collecting duct 1
• This blockade directly impairs the kidney's ability to excrete potassium, leading to accumulation in the bloodstream 1
• The effect is predictable and dose-dependent, allowing for early identification and monitoring of at-risk patients 2

Why Finerenone is Different from Steroidal MRAs

• Finerenone has higher selectivity for the mineralocorticoid receptor compared to spironolactone and stronger MR-binding affinity than eplerenone 3
• Despite this selectivity, finerenone still causes hyperkalemia, though the risk may be somewhat lower than with steroidal MRAs like spironolactone 4, 5
• The nonsteroidal structure does not eliminate hyperkalemia risk—it remains a class effect of all mineralocorticoid receptor antagonists 6, 7

High-Risk Patient Populations

Chronic Kidney Disease (Stage 3-4)

• Reduced eGFR is the strongest independent risk factor for hyperkalemia with finerenone, as impaired renal function limits potassium excretion capacity 8
• Patients with eGFR 25-60 mL/min/1.73 m² have substantially elevated risk, particularly when baseline potassium is already in the upper normal range 9, 10, 7
• Advanced CKD (up to 73% hyperkalemia incidence) dramatically amplifies risk when combined with MRA therapy 1

Concomitant RAAS Inhibitor Therapy

• ACE inhibitors and ARBs independently reduce potassium excretion by decreasing aldosterone secretion and reducing distal sodium delivery 1
• The combination of finerenone with ACE inhibitors or ARBs creates additive hyperkalemia risk, as both drug classes impair renal potassium handling through complementary mechanisms 1
• In FIDELIO-DKD, hyperkalemia led to 2.3% discontinuation with finerenone vs 0.9% with placebo, demonstrating the clinical impact of this combination 9, 10, 7

Type 2 Diabetes

• Diabetic patients often have hyporeninemic hypoaldosteronism (type 4 renal tubular acidosis), which already impairs potassium excretion 11
• Insulin deficiency in poorly controlled diabetes impairs cellular potassium uptake via Na/K-ATPase, keeping more potassium in the extracellular space 11
• Diabetic kidney disease combines multiple risk factors: reduced eGFR, albuminuria, and frequent RAAS inhibitor use 2, 8

Older Adults

• Age-related decline in renal function (even with "normal" creatinine due to reduced muscle mass) reduces potassium excretion capacity 1
• Older patients are more likely to be on multiple potassium-affecting medications: beta-blockers, NSAIDs, trimethoprim 1
• Female sex is an independent risk factor for hyperkalemia with finerenone, possibly due to lower muscle mass and different pharmacokinetics 8

Additional Contributing Factors

Medication Interactions

• Beta-blockers impair cellular potassium uptake by blocking β2-adrenergic receptors that normally drive Na/K-ATPase 1
• NSAIDs reduce renal potassium excretion by inhibiting prostaglandin-mediated renin release and reducing GFR 1
• Trimethoprim blocks epithelial sodium channels (ENaC) in the collecting duct, mimicking amiloride's effect 1

Baseline Potassium and Albuminuria

• Higher baseline serum potassium is an independent predictor of subsequent hyperkalemia with finerenone 8
• Increased urine albumin-creatinine ratio independently increases hyperkalemia risk, likely reflecting more severe kidney disease 8

Protective Factors

• Diuretic use (loop or thiazide) reduces hyperkalemia risk by increasing distal sodium delivery and potassium excretion 8
• SGLT2 inhibitor use reduces hyperkalemia risk by promoting natriuresis and improving tubular function, though the combination with finerenone still carries risk 8, 12

Clinical Implications

Monitoring Requirements

• Potassium must be ≤4.8 mmol/L before initiating finerenone per trial protocols 4, 7
• Check potassium within 1 week of starting finerenone, then at 1 month, and periodically thereafter based on risk factors 4, 6
• Patients with eGFR <60 mL/min, diabetes, or on RAAS inhibitors require more frequent monitoring (every 1-2 weeks initially) 4, 7

Management Strategy

• Finerenone should be withheld when potassium >5.5 mmol/L and restarted at 10 mg daily once potassium ≤5.0 mmol/L 8
• Temporary dose reduction or discontinuation at potassium >6.0 mmol/L is recommended, with reinitiation at lower dose once stable 4, 7
• Newer potassium binders (patiromer, sodium zirconium cyclosilicate) enable continuation of finerenone in patients who develop hyperkalemia, preserving cardiorenal benefits 4, 6, 13

Key Pitfall to Avoid

Do not permanently discontinue finerenone for a single episode of mild hyperkalemia (5.0-5.5 mmol/L)—instead, address contributing factors (NSAIDs, dietary potassium, dehydration), optimize diuretics, and consider potassium binders to maintain this life-saving therapy 4, 6, 13